Drug intelligence / Profile preview

PGS-N005

Development stage: Discontinued
Lead developer: BetterLife Pharma
Modality: Small Molecules
Administration: Topical

Overview

PGS-N005 is a topical cannabinoid-based formulation developed for the treatment of Female Sexual Dysfunction, specifically Hypoactive Sexual Desire Disorder (HSDD). The product utilizes the proprietary BiPhasix™ (or Thrudermic) multi-lamellar liposomal delivery system, which is designed to facilitate the transdermal absorption and bioavailability of cannabinoids. Developed by Pivot Pharmaceuticals (now BetterLife Pharma), PGS-N005 aims to modulate the endocannabinoid system to address issues related to sexual desire and arousal. While it was a lead candidate in the company's cannabis-focused pipeline between 2017 and 2020, development appears to have stalled as the company pivoted its focus toward psychedelic-based therapies.

Targets

CNR1 (Cannabinoid receptor 1)

Beyond the preview

Go deeper on PGS-N005.

Explore the evidence, development activity, and competitive landscape with Gosset’s full data platform.

Clinical trials

Follow clinical development from study design and recruitment through results.

Trial phase
Status
Readouts

Indications & development

Explore development by indication, patient population, and geography.

Indications
Development status
Countries

Licensing & deals

Trace asset ownership, licensing agreements, and commercial partnerships.

Partners
Deal terms
Milestones

Patents & exclusivity

Explore the patent landscape and regulatory exclusivity around an asset.

Patents
Expiration dates
Exclusivity

Competitive landscape

Compare development programs by target, modality, and indication.

Competing assets
Targets
Development stage

Research & analysis

Connect source evidence and development news to your research questions.

Publications
News
Analysis

Bring the full picture into focus.

See how Gosset can support your research on PGS-N005.

Explore the full profile